VHH in

Cell Therapies

Small, stable and robust, VHH offer an attractive construct for incorporation as targeting agents in cell therapies.

VHH can also be easily multimerised to meet a variety of therapeutic needs, enabling refined cell targeting and modes of action while also minimising off-target toxicity. Away from the ectodomain, their small size also permits packaging of more sophisticated intracellular signalling domains, supporting the next generation of cell therapies.

Advantages of

VHH in Cell Therapy

Smaller constructs mean more space for multi-specific targeting modules or next-generation signalling domains.

References:
1. Jayaraman J et al. (2020) Ebiomedicine 58: 102931
2. Lamers CH, et al. (2011) Blood 117(1):72-82
3. Ackaert C et al. (2021) Front. Immunol. 12: 632687
4. Desmyter A et al. (1996) Nat Struct Biol 3(9): 803-811


Download our poster on CAR-T

 *
 *
 *
 *
*
*Required Fields
Note: It is our responsibility to protect your privacy and we guarantee that your data will be completely confidential.

Isogenica’s

VHH in CAR-T Resources

Partnerships at Isogenica

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.